MOST NOTEWORTHY: In addition to Genomic Health (GHDX) and Intercontinental Hotels Group (IHG), airliners
Continental Airlines (CAL) and ExpressJet Holdings (XTJ) were some of today's most notable initiations:
- RBC Capital Markets started Genomic Health Inc (NASDAQ: GHDX) with an Underperform rating, with a $17 target. The firm views shares as fairly valued and believes competitive noise and FDA concerns will weigh on shares.
- HSBC started Intercontinental Hotels (NYSE: IHG) with an Overweight rating, believing asset sales and stronger than expected room growth could prove near-term positive catalysts.
- Soliel started both Continental Airlines (NYSE: CAL) and ExpressJet Holdings Inc (NYSE: XJT) with Sell ratings.
OTHER INITIATIONS:
- William Blair started Alexion Pharmaceuticals (NASDAQ: ALXN) with an Outperform rating. They believe Alexion's lead compound, Soliris, is the key driver of shareholder value, and they believe the company is well positioned to receive final FDA approval.
- Bear Stearns initiated Baldor Electric Company (NYSE: BEZ) with an Outperform rating.
- RBC initiated Hologic, Inc (NASDAQ: HOLX) with an Outperform rating.
- Citigroup started GMarket Inc (NASDAQ: GMKT) with a Sell rating and $18 target, citing valuation.
- Drew Industries, Inc (NYSE: DW) was initiated with a Buy rating and $35 target at Ferris Baker Watts.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required). 
Is a second stimulus check up ahead?
Coke (KO) moving up nicely following Q3 earnings
Will Lehman bankruptcy drop a $400 billion shoe on October 21st?
Reader Comments (Page 1 of 1)
3-09-2007 @ 1:32AM
zhaolan said...
Please tell me to treat PNH new medicine eculizumab whether already through FDA authorization? When may buy this kind of medicine? May buy in where? Please help me! Thanks!